StemSmart™ MSC – Pulmonary Fibrosis
Lung Inflammatory Disease
PreclinicalPlanned
Key Facts
Indication
Lung Inflammatory Disease
Phase
Preclinical
Status
Planned
About Neuroscientific Biopharmaceuticals
Australian MSC biotech advancing StemSmart™ therapy for Crohn’s disease and other inflammatory disorders.
View full company profile